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Abstract
Background: A sedentary lifestyle and poor diet are risk factors for the progression of non-alcoholic fatty liver
disease. However, the pathogenesis of hepatic lipid accumulation is not completely understood. Therefore, the
present study explored the effects of dietary supplementation of various ratios of docosahexaenoic acid (DHA) and
eicosapentaenoic acid (EPA) on a high-fat diet-induced lipid metabolism disorder and the concurrent liver damage.
Methods: Using high-fat diet-fed C57BL/6 J mice as the animal model, diets of various ratios of DHA/EPA (2:1, 1:1, and
1:2) with an n-6/n-3 ratio of 4:1 were prepared using fish and algae oils enriched in DHA and/or EPA and sunflower
seed oils to a small extent instead of the high-fat diet.
Results: Significantly decreased hepatic lipid deposition, body weight, serum lipid profile, inflammatory reactions, lipid
peroxidation, and expression of adipogenesis-related proteins and inflammatory factors were observed for mice that
were on a diet supplemented with DHA/EPA compared to those in the high-fat control group. The DHA/EPA 1:2 group
showed lower serum triglycerides (TG), total cholesterol (TC), and low-density lipoprotein-cholesterol levels, lower
SREBP-1C, FAS, and ACC-1 relative mRNA expression, and higher Fra1 mRNA expression, with higher relative mRNA
expression of enzymes such as AMPK, PPARα, and HSL observed in the DHA/EPA 1:1 group. Lower liver TC and TG
levels and higher superoxide dismutase levels were found in the DHA/EPA 2:1 group. Nonetheless, no other notable
effects were observed on the biomarkers mentioned above in the groups treated with DHA/EPA compared with the
DHA group.
Conclusions: The results showed that supplementation with a lower DHA/EPA ratio seems to be more effective at
alleviating high-fat diet-induced liver damage in mice, and a DHA/EPA ratio of 1:2 mitigated inflammatory risk factors.
These effects of n-3 polyunsaturated fatty acids (PUFA) on lipid metabolism may be linked to the upregulation of Fra1
and attenuated activity of c-Jun and c-Fos, thus ultimately reducing the severity of the lipid metabolism disorder and
liver damage to some extent.
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Background
An unhealthy lifestyle involving poor dietary habits
and low physical activity is a risk factor for the pro-
gression of non-alcoholic fatty liver disease (NAFLD)
[1]. Although it is generally believed that nutrient
modulation is a positive means to alleviate this prob-
lem [2] since the type and quantity of fat consumed
regulate hepatic lipid composition and gene expres-
sion [3], the pathogenesis of hepatic lipid accumula-
tion is not completely understood [4].
Decreasing dietary saturated fatty acid (SFA) intake [5]
and replacing it with polyunsaturated fatty acids (PUFA)
[6] has been advocated as the main dietary strategy to
prevent NAFLD caused by anti-inflammatory, antioxida-
tive, and hypolipidemic effects of PUFAs. Meanwhile,
long-chain PUFAs, mainly n-6 PUFA and n-3 PUFA, es-
pecially eicosapentaenoic (C20:5 n-3, EPA) and docosa-
hexaenoic (C22:6 n-3, DHA) acids, have frequently been
reported to influence NAFLD risk factors [7]. Reduced
hepatic lipid content with concomitant antioxidant and
anti-inflammatory responses favoring insulin sensitivity
in mice with high-fat diet-induced obesity are ascribed
to the repletion of liver n-3 PUFA levels by n-3 PUFA
dietary supplementation [7]. Nevertheless, evidence sug-
gests that selectively increasing the n-3 PUFA propor-
tion of the total PUFA intake [8, 9] has more significant
inhibitory effects on inflammation and NAFLD than
simply increasing n-3 PUFA intake [10]. Interestingly,
several studies have also demonstrated the latent effects
of the dietary proportion of n-6/n-3 on liver damage
[10, 11], and a low n-6/n-3 ratio was shown to be more
effective for the prevention of diet- or obesity-induced
fatty liver than that of a high n-6/n-3 ratio. Conse-
quently, a reasonable proportion of n-6/n-3 should be
taken into consideration when investigating the effects
of PUFAs on NAFLD [10].
Recently, there has been an increasing interest in the
effects of various ratios of DHA and EPA on chronic
diseases in rat models [12–15], and studies conducted to
evaluate these effects suggest that both n-6/n-3 ratios
and DHA/EPA ratios should be considered simultan-
eously. Additionally, our research group has previously
reported that DHA and EPA from fish and algal oils are
more beneficial than plant oils enriched in α-linolenic
acid (C18:3 n-3, ALA) at delaying atherosclerosis pro-
gression in model apoE−/− mice; an intervention with
higher DHA/EPA ratios was found to be beneficial for
reducing high cholesterol concentrations in the blood
[16]. Nevertheless, DHA and EPA differ in their physio-
logical functions, and a new study indicated that DHA
supplementation leads to a greater reduction in specific
markers of inflammation than that by an equal dose of
EPA [17]. In view of these observations, it remains un-
clear whether DHA is more effective than DHA/EPA,
there is an optimal ratio of DHA and EPA supplementa-
tion for reduction of high-fat diet-induced liver damage,
and regularizing the ratio of DHA and EPA has differen-
tial effects on various symptoms.
Therefore, in the present study, we sought to investi-
gate the role of dietary interventions with various ratios
of DHA/EPA (2:1, 1:1, and 1:2) in high-fat diet-induced
liver damage at an n-6/n-3 ratio of 4:1, which is optimal
for human health as recommended by the World Health
Organization (WHO). Healthy C57BL/6 J mice were
employed as animal models. Mice were fed high-fat diets
supplemented with sunflower seed, algae, and fish oils
containing different DHA/EPA ratios (2:1, 1:1, and 1:2).
Methods
Animals and diets
Ninety healthy male C57BL/6 J mice (age, 5 weeks;
weight, 18 ± 2 g) were supplied by Hubei Research
Center of Laboratory Animals (Wuhan, China) with
animal license SCXK (Hubei) 2008–0005. Animal exper-
iments described in this study were conducted with the
approval of the Tongji Medical College Council on
Animal Care Committee and in accordance with the
Guiding Principles of the Care and Use of Laboratory
Animals published by the US National Institutes of
Health. Before the mice were randomized into six
groups (n = 15), they were acclimated to the laboratory
for 7 days with basic feed, which was purchased from
WQJX Bio-technology (Wuhan, China). High-fat diet I
(HFD I) was composed of 700 g of basic feed, 150 g of
lard, 100 g of yolk powder, 40 g of casein, and 10 g of
cholesterol per kg. In high-fat diet II (HFD II), the
150 g/kg lard was reduced to 100 g/kg. The normal con-
trol group (NC) was fed with basic feed; the high-fat
control group (HFC) was fed with HFD I; the DHA
group received HFD II plus algal oils (containing 100 mg
of DHA per 260 mg) and sunflower seed oil (containing
n-6 PUFA at 60% but low amount of n-3 PUFA, adjust-
ing the proportion of n-6/n-3 to 4:1); and the DHA/EPA
group was fed HFD II as well as fish oils (containing
200 mg DHA and 400 mg EPA per 1900 mg) and algal
oils to achieve various DHA/EPA ratios (2:1, 1:1, and 1:2),
and sunflower seed oils to adjust the n-6/n-3 ratio to 4:1.
The total caloric intakes of mice in all groups were equiva-
lent except for mice in the NC group. The fatty acid com-
positions of oils, basic feed, control diet, and high fat diets
are described in Table 1. The PUFAs were administered
orally (0.75 mg/g body weight) every day for 11 weeks,
and NC as well as HFC mice were given the same dose of
distilled water via intragastric administration as control
groups. The mice were individually housed in a humidity-
and temperature-controlled room (relative humidity 60%
and temperature 20–22 °C) with a 12-h light/dark cycle
environment and were provided ad libitum access to
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water and their group-specific diet. Measurements of
body weight and food intake were taken weekly. After
11 weeks, five mice from each group were anesthe-
tized with isoflurane, and blood was drawn through
the retro-orbital sinus puncture prior to killing the
mice by decapitation after an overnight fast and used
for analyses to ensure the establishment of models of
steatosis and liver lesions. The rest of the mice were
euthanized in the same way. Serum was collected
from blood, subsequently centrifuged (4000×g, 4 °C,
10 min) after incubation at room temperature for
2 h, and then stored at −80 °C until analysis. Fresh
liver tissue samples were collected for histopathology
analysis or were rapidly frozen and stored at −80 °C
before use.
Analysis of steatosis and liver lesions
The liver was removed and weighed immediately after
the mice were euthanized. Liver fragments were sec-
tioned at a thickness of 5 μm, and fixed with 4%
paraformaldehyde overnight. Then the slices were
stained with oil red O, in order to analyze the
steatosis and liver lesions. Images were acquired by means
of an inverted fluorescence microscope (Olympus Co.,
Japan) equipped with a SONY DXC-970MD color video
camera, and analyzed using the Image-Pro plus program.
Measurement of serum and liver lipid profiles
The serum triglyceride (TG), total cholesterol (TC),
high-density lipoprotein-cholesterol (HDL-C), and low-
density lipoprotein-cholesterol (LDL-C) levels were
measured using similar commercial kits (Biosino Bio-
technology Co., Ltd., Beijing, China) with spectrophoto-
metric methods in accordance with the manufacturer’s
instructions.
To determine the hepatic TC and TG levels, 50 mg
of frozen liver tissue was placed in a test tube with
450 μl of isopropanol. The homogenate was incubated
at 4 °C for 36 h and then centrifuged at 4000×g and
4 °C for 10 min, and the supernatant was used for
analyses by means of the corresponding commercial
kits (Biosino Biotechnology Co., Ltd., Beijing, China)
with spectrophotometric methods in accordance with
the manufacturer’s instructions.
Table 1 Fatty acid composition of oils and mixed diets supplemented to mice
Fatty acid mg per 100 mg total fatty acid
Sunflower
seed oil






C14:0 0.1 0.3 8.7 0 0 0 2.6 1.4 0.8 0.1
C14:1 0 0.2 0.3 0 0 0 0.1 0.1 0.1 0.1
C15:0 0 0.5 0.2 0 0 0 0.1 0.1 0.1 0.1
C16:0 6.5 10.1 15.8 27.0 42.0 43.7 9.6 8.6 8.1 8
C16:1 0.1 4.7 3.5 0 1.8 1.7 1.1 1.1 1.2 1.5
C17:0 0 0.1 0.3 0 0 0 0.1 0.1 0.1 0
C17:1 0 0.1 0 0 0 0 0.0 0 0 0
C18:0 5.2 2.8 0 4.7 0.2 0.3 3.9 4.4 4.6 4.9
C18:1 24.9 7.9 13.5 21.2 16.5 15.6 22.8 22.2 22.4 22.2
C18:2(LA)n-6 60.7 1.9 1.6 36.9 21.5 21.7 46.4 48.4 49.3 49.9
C18:3(ALA)n-3 0 2 0 0 16.0 15.3 0.0 0.2 0.4 0.2
C20:1 0 0.1 0.3 0 0.13 0.12 0.1 0.1 0.1 0
C20:2 0 0.2 0 0 0 0 0.0 0 0 0.1
C20:4(AA)n-6 0 1.5 0.5 0.5 0.19 0.20 0.1 0.2 0.3 0.4
C20:5(EPA)n-3 0.2 35.1 0 0 0 0 0.2 4.3 6.2 8.1
C22:1 0 0.3 3.5 0 0 0 1.0 0.5 0.3 0.1
C22:5(DPA)n-3 0 2.4 0 0 0 0 0.0 0.3 0.4 0.6
C22:6(DHA)n-3 0 18.2 40.1 0 0 0 11.8 8 6 4.3
Total n-6 60.7 3.4 2.1 36.9 21.5 21.7 46.6 48.6 49.6 50.3
Total n-3 0.2 57.7 40.1 0 16.0 15.3 12.0 12.8 13 13.2
n6/n3 1.3 1.4 3.9 3.9 3.8 3.8
DHA/EPA 0 1.9 0 0 0 0 59.0 1.9 1 0.5
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Measurement of serum ALT, AST, GSH, SOD, MDA, and
inflammatory cytokines, and liver GSH, SOD, and MDA
The serum alanine aminotransferase (ALT), aspartate
aminotransferase (AST), glutathione (GSH), superoxide
dismutase (SOD), and malondialdehyde (MDA) were
measured by means of similar commercial kits (Nanjing
Jiancheng Corporation, Nanjing, China) in accordance
with the manufacturer’s recommendations. Serum tumor
necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β),
and interleukin-6 (IL-6) were determined using the cor-
responding commercial kits (Cloud-Clone Corp, Wuhan,
China) by ELISA methods according to the manufac-
turer’s instructions.
To analyze the hepatic levels of GSH, SOD, and MDA,
50 mg of liver tissues were homogenized with 450 μl of
normal saline. After centrifugation at 4000×g and 4 °C
for 10 min, the supernatant of the homogenate was used
for analysis with the corresponding commercial kits
(Nanjing Jiancheng Corporation) as specified by the
manufacturer. In addition, protein content was mea-
sured using commercial bicinchoninic acid (BCA) kits
(Cloud-Clone Corp, Wuhan, China).
Real-time PCR
The total RNA was extracted from liver tissues using the
RNAiso Plus reagents (TaKaRa BIO Inc., Dalian, China).
Then, the cDNA was extracted using a Prime Script RT
Reagent Kit (TaKaRa BIO Inc.). The mRNA was quanti-
fied with a real-time PCR machine (IQ5, Bio-Rad, USA)
using SYBR Premix Ex Taq (TaKaRa BIO Inc., Dalian,
China) and specific primers (BGI Tech Solutions Co.,
Ltd., Shenzhen, China) in accordance with the manufac-
turer’s recommendations. The forward and reverse
primers for the target genes are listed in Table 2. Relative
gene expression was normalized (by means of the CT
method) to that of the endogenous control β-actin, and
the final results were calculated using the formula 2−ΔΔCt.
Analysis of western blots
Protein expression levels of c-Jun, c-Fos, and Fra1
were analyzed by western blotting. Briefly, the total
protein was extracted in PMSF:RIPA = 1:99 (v/v), a
homogenizing and lysis buffer. Equal amounts of pro-
tein extracts, which were normalized to the total
amount of protein, were mixed (1:3, v/v) with the
loading buffer for electrophoresis using 10% SDS-
PAGE gels kits (Boster Bio-engineering, Ltd., Wuhan,
China). The mixture was subsequently electroblotted
to a nitrocellulose transfer membrane (Millipore,
USA) by a Trans-Blot SD semi-dry transfer cell (Bio-
Rad, USA) as per the manufacturer’s instructions. The
target protein levels were detected with specific pri-
mary antibodies (Bioss Biological Technology, Ltd.,
Wuhan, China) against the target protein, and then
incubated with the species-specific secondary anti-
body, horseradish peroxidase-conjugated anti-rabbit
IgG antibody (Boster Bio-engineering), as recom-
mended by the manufacturer. The chemiluminescence
intensity of the bands was quantified by an ECL de-
veloper (Millipore, USA) using a Western Blotting
Detection System (Bio-Rad, USA), and the optical
densities of the bands were detected using Image Lab
Table 2 Real-time quantitative PCR primer sequences
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5.1 software (Bio-Rad). Data were corrected to elimin-
ate background noise and were standardized to the
optical density (OD/mm2) of β-tubulin (Boster Bio-
engineering).
Statistical analysis
All data were recorded with Excel. After confirming the
homogeneity of variances, differences among the groups
were tested by one-way ANOVA. Means ± SEM were
calculated for each group, and the figures were prepared
using GraphPad Prism v6.0.1 software. The significant
differences were shown by the LSD multiple comparison
test using SPSS statistics 17.0 software, and any two
groups without the same lowercase and uppercase let-
ters, as marked in the figures, indicate a significant dif-
ference of P value <0.05 and <0.01, respectively.
Results
Effects of various ratios of DHA/EPA with an n-6/n-3 ratio
of 4:1 on steatosis and liver cell histopathological lesions
At 12 weeks post-administration, the histopathological
lesions of livers in all groups were assessed. The oil
red O staining patterns showed orange lipid droplets
and blue nuclei, which were smaller and fewer in
number in the DHA/EPA (2:1, 1:1, and 1:2) groups;
while obvious numerous orange-red lipid droplets
were observed in HFC-treated mice, nearly none were
observed in the NC group (Fig. 1). Moreover, fewer
lipid droplets were observed in mouse groups treated
with DHA/EPA (ratios of 2:1, 1:1, and 1:2) compared
to the group treated with DHA.
Effects of various ratios of DHA/EPA with an n-6/n-3 ratio
of 4:1 on body weight, serum, and liver lipids
Compared to the HFC group, significant decreases
(p < 0.05) in serum TC, TG, LDL-C levels, and liver TC
and TG levels were observed in 12-week n-3 PUFA sup-
plementation groups (Table 3). The growth curve of
mice revealed that the body weight increased slower
with n-3 PUFA supplementation than with HFC
treatment (Fig. 2), indicating the inhibitory effect of n-3
PUFA supplementation with DHA and different DHA/
EPA ratios (2:1, 1:1, and 1:2) in the mice. Moreover, mice
treated with a DHA/EPA ratio of 2:1 and 1:2 showed a
reduced hepatic organ coefficient with a significant dif-
ference of p < 0.01, while the statistical differences of re-
duction in DHA and DHA/EPA 1:1 groups were
p < 0.05 compared to those in the HFC group (Table 3).
Mice treated with a DHA/EPA ratio of 1:2 showed a
more appreciable decrease in serum TC, TG, and LDL-C
levels, whereas mice treated with the DHA/EPA ratio of
2:1 showed lowered liver TC and TG levels to a greater
degree. However, mice treated with various ratios of
DHA/EPA (2:1, 1:1, and 1:2) revealed no reduction in
serum TC, TG, or LDL-C levels or liver TC and TG
levels in comparison with those in the DHA group.
Nevertheless, as compared to the levels in the HFC
group, serum HDL-C levels in DHA and DHA/EPA (2:1,
1:1, and 1:2) groups were significantly higher (p < 0.01).
Furthermore, serum HDL-C levels increased more sig-
nificantly in the DHA/EPA 1:2 group than in other
DHA/EPA groups (p < 0.01), but the increase was not
remarkable in comparison to that in the DHA group.
Effects of various ratios of DHA/EPA with an n-6/n-3 ratio
of 4:1 on liver damage
Levels of serum ALT, AST, GSH, SOD, and MDA, and
liver GSH, SOD, and MDA are presented in Fig. 3. The
results show that treatment with n-3 PUFAs lowered the
levels of serum ALT and AST and both serum and liver
MDA production, and raised the levels of GSH and SOD
both in serum and liver in comparison with those in the
HFC group. Nonetheless, no significant differences were
found in the levels of any of these biomarkers between
the DHA and DHA/EPA groups. Nevertheless, supple-
mentation with a DHA/EPA ratio of 1:2 resulted in
greater reduction in serum ALT, AST, and MDA levels
and increase of serum GSH levels among the DHA/EPA
groups; however, this increase was not higher than that
observed in DHA groups. Collectively, supplementation
with a DHA/EPA ratio of 2:1 was the most effective
among the three DHA/EPA groups at enhancing SOD
levels both in serum and liver, but these levels were not
higher than those in the DHA group. Particularly, mice
treated at a DHA/EPA ratio of 1:1 showed increased
liver GSH levels as compared to the DHA group
(2.828 ± 0.279 vs. 2.612 ± 0.546 mg/g prot).
Effects of various ratios of DHA/EPA with an n-6/n-3 ratio
of 4:1 on lipid metabolism genes
Gene expression variation of the enzymes and transcrip-
tion factors of lipid metabolism was measured by real-
time PCR as shown in Fig. 4. Compared to the HFC
group, 43%, 27%, 46%, and 27% increases in AMPK
Fig. 1 Effects of DHA/EPA on steatosis and liver cell histopathological
lesions in high-fat diet-induced mice. Slices of liver tissues stained with
oil red O (n = 5, ×200)
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(AMP-activated protein kinase) mRNA expression, and
103%, 68%, 84%, and 92% increases in ACOX (acyl-co-
enzyme A oxidase) mRNA expression, were demon-
strated in DHA groups and groups with the DHA/EPA
ratio of 2:1, 1:1, and 1:2, respectively. Noticeably, mice
treated with a DHA/EPA ratio of 1:2 showed a greater
reduction in SREBP-1C (sterol regulatory element bind-
ing protein-1C), SCD-1 (stearoyl-CoA desaturase-1),
FAS (fatty acid synthase), ACC-1 (acetyl CoA
carboxylase-1), and PPARγ (peroxisome proliferator acti-
vated receptor gamma) mRNA expression, while the
DHA/EPA 1:1 group showed higher HSL (hormone sen-
sitive lipase), PPARα, and CPT-1 (carnitine palmitoyl
transferase-1) mRNA expression, among the DHA/EPA
groups. Particularly, the group treated with the DHA/
EPA ratio of 1:2 showed lowered SCD-1 mRNA expres-
sion, and the DHA/EPA 1:1 group showed enhanced
CPT-1 mRNA expression, whereas no significant differ-
ences were observed in the DHA group.
Effects of various ratios of DHA/EPA with an n-6/n-3 ratio
of 4:1 on the inflammatory response
The protein expression levels of the three main subunits
of AP-1 (c-Jun, c-Fos, and Fra1) were detected by
western blot (Fig. 5a–d). The protein expression levels of
c-Jun and c-Fos were significantly lower in the DHA/
EPA groups compared to the HFC group (p < 0.01),
meanwhile supplementation with a DHA/EPA ratio of
1:1 revealed greater reductions in the expression levels
of these two proteins in contrast to the DHA group.
Nonetheless, the protein expression levels of Fra1 were
found to be significantly higher in the DHA and DHA/
EPA treated groups in comparison to the HFC group
(p < 0.05). Supplementation with DHA/EPA at the ratio
of 1:2 did not result in enhancement in Fra1 expression
levels. The mRNA expression levels related to c-Jun,
c-Fos, and Fra1 were quantified by real-time PCR
(Fig. 5e–g). Supplementation with n-3 PUFA showed
a significant decrease in c-Jun and c-Fos mRNA ex-
pression and an increase in Fra1 mRNA expression,
as compared to those in the HFC group (p < 0.05).
Moreover, mice treated with the DHA/EPA ratio of
1:1 and 1:2 showed lowered c-Jun and c-Fos mRNA
expression, respectively, in comparison to those in the
DHA group. Nevertheless, no significant increase in
Fra1 mRNA expression was observed in the best per-
formance group (treated with the DHA/EPA ratio of
1:2) as compared with the DHA group.
The concentrations of serum TNF-α, IL-1β, and IL-6
were all significantly lower in the DHA and the DHA/
EPA groups as compared to those in HFC group
(p < 0.05) (Fig. 6). The quantitative real-time PCR
assay, which roughly identified the inflammatory cyto-
kine levels, revealed significantly decreased expression
of TNF-α, IL-1β, and IL-6 in liver tissues of DHA/EPA-
treated mice in comparison to those in HFC-treated
mice (p < 0.05). Furthermore, mice treated with a
DHA/EPA ratio of 2:1 revealed greater decreases in
serum TNF-α contents and its mRNA expression levels
in contrast to the DHA group. Additionally, supple-
mentation with a DHA/EPA ratio of 1:2 demonstrated a
more obvious reduction in serum IL-1β and IL-6 con-
tents, and their mRNA expression as compared to
those in the DHA group.
Table 3 Effects of various ratios of DHA/EPA on serum and liver lipids in high-fat diet-induced mice






Serum TC/(mmol/L) 3.693 ± 0.298aA 5.175 ± 0.368bB 3.559 ± 0.246aA 4.144 ± 0.323aAB 4.058 ± 0.181aA 3.935 ± 0.180aA
Serum TG/(mmol/L) 1.198 ± 0.045bB 1.388 ± 0.029cC 0.862 ± 0.035aA 0.981 ± 0.060aA 0.986 ± 0.028aA 0.879 ± 0.046aA
Serum HDL-C/(mmol/L) 1.144 ± 0.044cdBC 0.791 ± 0.028aA 1.270 ± 0.043dC 1.015 ± 0.017bB 1.128 ± 0.038bcBC 1.267 ± 0.029dC
Serum LDL-C/(mmol/L) 1.954 ± 0.082bcB 2.654 ± 0.055dC 1.600 ± 0.081aA 2.158 ± 0.087cB 2.070 ± 0.076bcB 1.914 ± 0.067bB
Liver TC/(mmol/L) 1.276 ± 0.099aA 2.452 ± 0.101dD 1.515 ± 0.078bAB 1.689 ± 0.055bcBC 1.811 ± 0.055cBC 1.823 ± 0.038cC
Liver TG/(mmol/L) 3.559 ± 0.184bAB 6.177 ± 0.330dD 2.693 ± 0.166aA 4.293 ± 0.100cBC 4.494 ± 0.350cC 4.538 ± 0.172cC
hepatic organ coefficient /(g/100 g) 3.835 ± 0.098aA 4.268 ± 0.037bB 4.019 ± 0.080aAB 3.934 ± 0.097aA 4.033 ± 0.037aAB 3.939 ± 0.060aA
Note: Each value is the mean ± SEM (n = 8), and any two groups without the same lowercase or uppercase letters, as marked in the table, indicate a significant
difference of p < 0.05 and p < 0.01, respectively
Fig. 2 Effects of various ratios of DHA/EPA on growth of high-fat
diet-induced mice. Each value is a mean ± SEM (n = 10)
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Fig. 3 (See legend on next page.)
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Discussion
The n-3 PUFAs, principally DHA and EPA, have been
reported to play an increasingly significant role in the
growth and health of the human body as shown by many
previous studies [9, 10]. The physiological functions of
n-3 PUFAs have attracted increasing interest because of
the increasing number of people choosing to lead
healthy lifestyles [18]. However, there was a tendency
among most attempted studies to focus on the effects of
an individual n-3 or n-6 PUFA or the ratio of n-6/n-3,
which did not take the possible influence of the relative
ratio of DHA and EPA on the results into account [15].
A marked increase in the n-6/n-3 ratio is associated with
lipogenesis, overweight lipid oxidation and secretion, and
therefore promotion of NAFLD [11]; fish oil intake varies
in its hepatic fatty acid composition in supplements with
n-3 PUFA, and a reduction in the n-6/n-3 ratio has
already been revealed in another study [7]. Other reports
demonstrated that DHA supplementation led to a greater
reduction in specific makers of inflammation than that by
an equal dose of EPA [17], but supplementation with
varying ratios of EPA/DHA influenced different meta-
bolic syndrome markers [15] and enhanced the posi-
tive effects of biomarkers of inflammation [12].
Accordingly, in the present study, we concentrated on the
effects of various ratios of DHA/EPA (with an n-6/n-3
ratio of 4:1) on liver damage in C57BL/6 J mice with high-
fat diet-induced obesity.
High-fat diets enriched in saturated fat may promote
an increase in body weight and lead to obesity, liver in-
jury, hepatic insulin resistance, and steatosis [19]. Treat-
ment with increasing amounts of n-3 PUFA, however,
seems to reduce the rate of increase in body weight [20].
A study showed that animals on high-fat diets appeared
to have an increased ability to store TG, whereas animals
fed high fish oil diets (along with consumption of excess
calories) did not convert excess lipids into TGs [19].
These data appear to be in agreement with our current
study showing that lower TG levels both in serum and
in the liver were found in groups that were treated with
n-3 PUFAs compared with the HFC group. Meanwhile,
all n-3 supplementation groups showed attenuation of
body weight gain compared to that in the untreated con-
trol. EPA and DHA oil reduced total body fat [21],
wherein reduced hepatic lipid deposition was observed
in n-3 groups in the present study. Our results revealed
that DHA and DHA/EPA supplementation decreased
hepatic TG and TC levels possibly through reducing the
release of TG and TC into the blood plasma for liver tis-
sues, simultaneously improving serum HDL-C levels.
Therefore, DHA and DHA/EPA supplementation inhib-
ited hepatic lipid profile deterioration in mice with high-
fat diet-induced obesity. Additionally, groups with a
DHA/EPA ratio of 1:2 with an n-6/n-3 ratio of 4:1
showed the lowest serum levels of TG, TC, and LDL-C,
and the highest concentration of serum HDL-C, while
the lowest liver TC and TG levels were observed in the
DHA/EPA 2:1 group among the DHA/EPA groups.
Nevertheless, the best performance groups treated
with DHA/EPA did not show better results than
those in the DHA group. These findings seemed to
contradict our previous report that indicated that
serum TC and LDL-C levels were the lowest in the
2:1 DHA/EPA group, because the highest serum
HDL-C content was observed in the 1:1 DHA/EPA
group in apoE−/− mice [16]. These findings may be
explained by the lack of apoE, a ligand for receptors
that clear remnants of chylomicrons and very low
(See figure on previous page.)
Fig. 3 Effects of various ratios of DHA/EPA on liver damage in high-fat diet-induced mice. Serum ALT (a), AST (b), MDA (c), GSH (d), SOD (e), and
liver MDA (f), GSH (g), SOD (h) levels were measured with the corresponding commercial kits. Each value is the mean ± SEM (n = 6), and any two
groups without the same lowercase or uppercase letters, as marked in the figures, indicate a significant difference of p < 0.05 and
p < 0.01, respectively
Fig. 4 Effects of DHA/EPA on relative lipid metabolic gene expression
in high-fat diet-induced mice. The relative mRNA expression of genes
involved in fatty acid synthesis (a) and fatty acid oxidation (b) in liver
tissues analyzed by real-time PCR. Each value is the mean ± SEM
(n = 8), any two groups without the same lowercase or uppercase
letters, as marked in the figures, indicate a significant difference of
p < 0.05 and p < 0.01, respectively
Shang et al. Lipids in Health and Disease  (2017) 16:65 Page 8 of 13
density lipoproteins, and accumulation of apoE is ex-
pected to cause accumulation in plasma of cholesterol-
rich residues [22].
The n-3 PUFAs exerted their effects on the lipid pro-
files through their abilities to upregulate genes encoding
proteins involved in fatty acid oxidation, while concur-
rently downregulating genes encoding proteins involved
in lipid synthesis [15]. For example, n-3 PUFAs down-
regulate the transcription factor SREBP-1 [23, 24], which
upregulates lipogenic genes, FAS and SCD-1, promoting
TG accumulation in the liver [25]. However, little was
previously known about how different ratios of DHA/
EPA affect various pathways involved in lipid metabol-
ism in the liver. Thus, in order to understand the mech-
anism of action underlying the differences in lipid
profile and liver lipid deposition caused by DHA/EPA
supplementation, the mRNA expression levels of the fol-
lowing proteins were analyzed: SREBP-1C [26], SCD-1
[27], FAS [28], ACC-1 [4], and HSL [29], which are pro-
teins involved in lipogenesis; and AMPK [30], PPARα
Fig. 5 Effects of various ratios of DHA/EPA on relative protein expression in high-fat diet-induced mice. a Bands of c-Jun, c-Fos, and Fra1 obtained
by western blotting. The western blot results of c-Jun (b), c-Fos (c), and Fra1 (d) in liver tissues. The mRNA expression of c-Jun (e), c-Fos (f), Fra1
(g) in liver tissues as detected by real-time PCR. Each value is the mean ± SEM (n = 3), and any two groups without the same lowercase
or uppercase letters, as marked in the figures, indicate a significant difference of p < 0.05 and p < 0.01, respectively
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[31], PPARγ [31], CPT-1 [32], and ACOX [8], which are
proteins involved in fatty acid oxidation. Mice treated
with DHA/EPA showed promotion of the expression of
Fra1 protein and its relative mRNA expression, and in-
hibition of the expression of PPARγ mRNA, which po-
tentially indicated that DHA/EPA exert their effects on
lipid metabolic modulation by accelerating the expres-
sion of Fra1 and restraining the expression of PPARγ,
and thereby suppressing the expression of their down-
stream adipogenic genes. Moreover, a DHA/EPA ratio of
1:1 revealed the highest expression of enzymes such as
AMPK, PPARα, and CPT-1 relative mRNA levels, there-
fore improving fatty acid oxidation in the liver. The low-
est relative mRNA expression levels of SREBP-1C, SCD-
1, FAS, and ACC-1 were observed in the DHA/EPA 1:2
group, which indicated that supplementation with DHA/
EPA is likely to alter fatty acid synthesis via upregulating
AMPK expression, which decreases the expression of
SREBP-1C and PPARγ, thereby reducing downstream
expression of key enzymes (ACC-1, FAS, and SCD-1) in
the liver. Consequently, the central protein that balances
energy metabolism in the body, Fra1, plays a vital role in
lipid metabolism by inhibiting the gene expression of
PPARα, reducing SCD-1 levels, and decreasing de novo
lipogenesis, which lowers hepatic lipid accumulation and
lipogenesis [33].
Overnutrition results in the onset of oxidative stress in
the liver because of higher availability and oxidation of
fatty acids [34], and high-fat diets increase hepatic stea-
tosis and hepatitis attributed to increased oxidative
stress [35]. Additionally, lowered activation of GSH and
SOD and increased MDA production both in serum and
liver were observed in the HFC group compared to the
NC group in the present study. Furthermore, evidence
of decreased lipid content was found in animal models
treated with n-3 PUFAs [36], whereby the improvement
Fig. 6 Effects of various ratios of DHA/EPA on inflammatory cytokines in high-fat diet-induced mice. Serum levels of TNF-α (a), IL-1β (b), and IL-6
(c) as measured by ELISA (n = 8). The expression of TNF-α (d), IL-1β (e), IL-6 (f) in hepatic tissues as measured by real-time PCR (n = 10).
Each value is the mean ± SEM, and any two groups without the same lowercase or uppercase letters, as marked in the figures, indicate
a significant difference of p < 0.05 and p < 0.01, respectively
Shang et al. Lipids in Health and Disease  (2017) 16:65 Page 10 of 13
in lipid profile was principally caused by increased
fatty acid β-oxidation and suppression of fatty acid
synthesis in the liver by PUFAs [37]. MDA produc-
tion was remarkably decreased by PUFA supplementa-
tion, and the inhibitory effects of mixed plant oils
and DHA/EPA on MDA production were shown to
be significantly different [16]. In the present study,
we observed increased activation of GSH and SOD,
which may explain the higher antioxidant capacity
[14], and decreased MDA production was observed
both in serum and in the liver in the DHA/EPA
groups in comparison with that in the HFC group.
Furthermore, the effects of various DHA/EPA ratios
with a balanced n-6/n-3 ratio of 4:1 on liver damage
biomarkers were investigated here, and lowered con-
centrations of serum ALT and AST were found.
Nonetheless, a stronger effect was not observed in
the best performance group among DHA/EPA groups
as compared with the DHA group in mice with high-
fat diet-induced obesity. Accordingly, the ability of
DHA/EPA with an n-6/n-3 ratio of 4:1 to modulate
the alteration in lipid oxidation and hepatic oxidative
damage was substantial; this result is in line with an
existing report showing that supplementation with
PUFAs induced changes in the oxidation state [16].
NAFLD, which ranges from simple hepatic steatosis to
steatohepatitis, can be complicated with inflammation
[34]. In NAFLD, cholesterol deposited in cytoplasmic
droplets stimulates the secretion of pro-inflammatory
factors, which amplifies the local inflammatory reaction
and causes the production of ROS [16]. Regular intake
of n-3 PUFA, mainly EPA and DHA, provides metabolic
health benefits by altering the production of specific
lipid biomarkers of cellular inflammation [38]. This ob-
servation is in agreement with the current study, which
indicated that DHA/EPA supplementation attenuates in-
flammation by reducing levels of inflammatory risk fac-
tors. Although it has been proposed that DHA is more
beneficial in terms of its anti-inflammatory effects as
shown in various cellular models [39], it has been re-
ported that supplementation with EPA/DHA at ratios of
1:1 and 2:1 reduces the inflammatory C reactive protein
index more significantly than the ratio of 1:2 [13]. In the
present study, levels of inflammatory factors as well as
those of their relative gene expression decreased obvi-
ously; the biggest reduction in TNF-α levels was found
in the DHA/EPA 2:1 group, while the lowest levels of
IL-1β and IL-6 were observed in the DHA/EPA 1:2
group with an n-6/n-3 ratio of 4:1. This result is consist-
ent with the observation of inflammation-dampening ef-
fects of n-3 PUFAs in the liver and a decreased
inflammatory response in fat-1 mice that is associated
with significantly reduced hepatic gene expression of
TNF-α, IL-1β, and IL-6 [40].
Cytokines involved in the complex inflammatory re-
sponse network can be modulated by various activa-
tors and inhibitors, thus, activating various reactions
in inflammatory pathways [41], which may amplify
the inflammatory reaction and result in tissue injury
if uncontrolled [42]. Among the typical inflammatory
responses of metaflammation, activating protein-1
(AP-1, including c-Jun and c-Fos) [43] is a relevant
type of inflammatory transcription factor [44] and an
important signal transduction pathway component of
proinflammatory mediator expression that is inde-
pendent of NF-κB [31]; its activity might be regulated
by gene transcription levels and protein concentration
[45]. The results of our present study suggest that
consumption of DHA/EPA significantly suppressed
the expression of c-Jun and c-Fos proteins and their
respective genes, with ratios of 1:1 and 1:2 showing
better effects than those by DHA, in HFD-induced
mice. Consequently, DHA/EPA reduced the expres-
sion of c-Jun and c-Fos proteins and weakened the
activity of AP-1, which may decrease the expression
of inflammatory factors; thus, this may have attenu-
ated the activation of inflammatory pathways as a
lower DHA/EPA ratio was found to be more effective
at alleviating an inflammatory response.
Conclusions
In summary, supplementation with various DHA/EPA
ratios composed of fish, algae, and sunflower seed oils
with an n-6/n-3 ratio of 4:1 was beneficial by means
of promoting lipid metabolic processes, attenuating
steatosis, and hepatic lipid accumulation, and by re-
lieving hepatocyte oxidative damage by regulating the
serum lipid profiles, controlling inflammatory reac-
tions, and balancing lipid peroxidation. These effects
of n-3 PUFA on lipid metabolism may be linked to
the improvement of Fra1 expression and the attenu-
ated activity of c-Jun and c-Fos, ultimately reducing
the severity of a lipid metabolism disorder and liver
damage to some extent. DHA/EPA did not yield bet-
ter results on modulation of the serum lipid profile,
oxidative damage, and expression of lipid metabolism-
related genes, but were more effective at controlling
inflammatory factors as compared to that by DHA. A
lower DHA/EPA ratio seems to be more beneficial for
alleviation of high-fat diet-induced liver damage in
mice, and a DHA/EPA ratio of 1:2 mitigated the in-
flammatory risk factors. Further research is required
to explain this discrepancy.
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